185 related articles for article (PubMed ID: 37418076)
41. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
42. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.
Braggio E; McPhail ER; Macon W; Lopes MB; Schiff D; Law M; Fink S; Sprau D; Giannini C; Dogan A; Fonseca R; O'Neill BP
Clin Cancer Res; 2011 Jul; 17(13):4245-53. PubMed ID: 21562036
[TBL] [Abstract][Full Text] [Related]
43. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract][Full Text] [Related]
44. Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis.
Shin DW; Kim JH; Kim YH; Cho YH; Hong SH
J Neurooncol; 2020 Apr; 147(2):339-349. PubMed ID: 32221784
[TBL] [Abstract][Full Text] [Related]
45. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
46. Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma.
Kawaguchi A; Iwadate Y; Komohara Y; Sano M; Kajiwara K; Yajima N; Tsuchiya N; Homma J; Aoki H; Kobayashi T; Sakai Y; Hondoh H; Fujii Y; Kakuma T; Yamanaka R
Clin Cancer Res; 2012 Oct; 18(20):5672-81. PubMed ID: 22908096
[TBL] [Abstract][Full Text] [Related]
47. Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
Bruno A; Labreche K; Daniau M; Boisselier B; Gauchotte G; Royer-Perron L; Rahimian A; Lemoine F; de la Grange P; Guégan J; Bielle F; Polivka M; Adam C; Meyronet D; Figarella-Branger D; Villa C; Chrétien F; Eimer S; Davi F; Rousseau A; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K; Alentorn A
Neuro Oncol; 2018 Jul; 20(8):1092-1100. PubMed ID: 29432597
[TBL] [Abstract][Full Text] [Related]
48. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576
[TBL] [Abstract][Full Text] [Related]
49. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
50. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
[TBL] [Abstract][Full Text] [Related]
51. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.
Griewank KG; Koelsche C; van de Nes JAP; Schrimpf D; Gessi M; Möller I; Sucker A; Scolyer RA; Buckland ME; Murali R; Pietsch T; von Deimling A; Schadendorf D
Clin Cancer Res; 2018 Sep; 24(18):4494-4504. PubMed ID: 29891723
[No Abstract] [Full Text] [Related]
52. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sobesky S; Mammadova L; Cirillo M; Drees EEE; Mattlener J; Dörr H; Altmüller J; Shi Z; Bröckelmann PJ; Weiss J; Kreissl S; Sasse S; Ullrich RT; Reinke S; Klapper W; Gerhard-Hartmann E; Rosenwald A; Roemer MGM; Nürnberg P; Hagenbeek A; Zijlstra JM; Pegtel DM; Engert A; Borchmann P; von Tresckow B; Borchmann S
Med; 2021 Oct; 2(10):1171-1193.e11. PubMed ID: 35590205
[TBL] [Abstract][Full Text] [Related]
53. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
54. Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion.
Andreiuolo F; Ferrone CK; Rajan S; Perry A; Guney E; Cham E; Giannini C; Toland A; Willard N; de Souza AS; Dazelle K; Chung HJ; Singh O; Conway K; Coley N; Dampier C; Abdullaev Z; Pratt D; Cimino PJ; Quezado M; Aldape K
Acta Neuropathol Commun; 2024 Mar; 12(1):42. PubMed ID: 38500181
[TBL] [Abstract][Full Text] [Related]
55. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.
Roth P; Keller A; Hoheisel JD; Codo P; Bauer AS; Backes C; Leidinger P; Meese E; Thiel E; Korfel A; Weller M
Eur J Cancer; 2015 Feb; 51(3):382-90. PubMed ID: 25534293
[TBL] [Abstract][Full Text] [Related]
56. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
57. Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.
Kinoshita M; Hashimoto N; Izumoto S; Okita Y; Kagawa N; Maruno M; Ohnishi T; Arita N; Yoshimine T
J Neurooncol; 2010 Aug; 99(1):95-101. PubMed ID: 20069343
[TBL] [Abstract][Full Text] [Related]
58. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
59. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
[TBL] [Abstract][Full Text] [Related]
60. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
